Athenex up on sale of certain rights for skin disorder drug
22/06/2022 17:11
** Shares of drugmaker Athenex Inc ATNX.O rise 2.9% to
$0.54
** Co sells rights to revenues from U.S. and European
royalty and milestone interests in Klisyri to Sagard Healthcare
Partners and funds managed by Oaktree Capital Management for $85
mln urn:newsml:reuters.com:*:nGNX99tjxP
** Klisyri is co's topical treatment for actinic keratosis
(AK), a type of a chronic and pre-cancerous skin disease
** At least $80 mln to be used toward debt paydown and to
fund operations - ATNX
** Including session moves, stock has lost ~60% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))